The Secretory Pathway and Endocytosis

Core Explanation

The Secretory Pathway (Outbound)

The secretory pathway consists of sequential compartments through which newly synthesized proteins pass en route to the plasma membrane or extracellular space:

Rough ER → ER Exit Sites (ERES) → ERGIC → cis-Golgi → medial-Golgi → trans-Golgi → TGN → Plasma Membrane / Secretion

ER exit sites (ERES): Specialized, ribosome-free ER subdomains where COPII vesicles form. Only properly folded and assembled proteins are allowed to exit — this is the first quality control checkpoint. Misfolded proteins are retained by ER chaperones (BiP, calnexin, calreticulin) and eventually targeted for ERAD (ER-associated degradation).

ERGIC (ER-Golgi intermediate compartment): A tubulovesicular cluster between the ER and cis-Golgi. COPII vesicles from ERES fuse with/fuse to form the ERGIC, which then matures or moves along microtubules to the cis-Golgi. The ERGIC also sends COPI vesicles back to the ER, retrieving escaped ER-resident proteins (via KDEL receptor and KKXX signals).

Golgi apparatus: A stack of flattened cisternae organized with polarity:

• cis-Golgi: Entry face, receives cargo from ERGIC. Initial carbohydrate modifications.
• medial-Golgi: Removal of mannose residues, addition of GlcNAc (N-acetylglucosamine).
• trans-Golgi: Addition of galactose and sialic acid.
• TGN (trans-Golgi network): Exit face. Sorting hub — cargo is sorted into carriers for the plasma membrane (constitutive or regulated secretion), endosomes/lysosomes, or back to earlier Golgi compartments.

Two models of Golgi transport are not mutually exclusive:

Modern consensus: Cisternal maturation is dominant for large cargo, while COPI vesicles recycle resident enzymes backwards as cisternae mature, maintaining the distinct enzyme composition of each cisterna.

Constitutive vs. Regulated Secretion

Regulated secretion — neurotransmitter release: Synaptic vesicles (~40 nm) are pre-loaded with neurotransmitter and docked at the presynaptic active zone. Action potential arrival opens voltage-gated Ca²⁺ channels; Ca²⁺ influx (from ~100 nM to ~10–100 μM) binds synaptotagmin, which displaces complexin, allowing SNARE zippering to complete. Fusion occurs within ~0.2 ms, releasing neurotransmitter into the synaptic cleft. The vesicle membrane is then retrieved by clathrin-mediated endocytosis and recycled (the synaptic vesicle cycle, taking ~20–60 seconds).

Endocytosis (Inbound)

Endocytosis internalizes extracellular material and plasma membrane components. Three major types:

1. Pinocytosis ("cell drinking"): Non-specific uptake of extracellular fluid and dissolved solutes via small vesicles (~100 nm). Can be clathrin-dependent or clathrin-independent (caveolae, macropinocytosis). Constitutive in most cells.

2. Phagocytosis ("cell eating"): Engulfment of large particles (>0.5 μm) — bacteria, apoptotic cells, debris. Specialized in macrophages, neutrophils, and dendritic cells. Activated by particle binding to cell-surface receptors (Fc receptors, complement receptors, scavenger receptors), which triggers localized actin polymerization that extends pseudopods around the particle. The resulting phagosome matures by fusing with lysosomes (phagolysosome) for degradation.

3. Receptor-mediated endocytosis (RME): Highly specific, efficient internalization of ligands via cell-surface receptors concentrated in clathrin-coated pits. ~2% of the plasma membrane is clathrin-coated pits, yet they account for the bulk of specific endocytic uptake. Cargo is concentrated 10–100 fold.

Mechanism: The LDL Receptor Pathway (Paradigm for RME)

The LDL (low-density lipoprotein) receptor pathway — discovered by Goldstein and Brown (Nobel Prize, 1985) — is the textbook example of receptor-mediated endocytosis:

Step 1: Receptor synthesis and surface expression. The LDL receptor is synthesized in the ER, processed through the Golgi, and delivered constitutively to the plasma membrane. Its cytoplasmic tail contains an NPXY motif essential for clustering into coated pits.

Step 2: LDL binding. The LDL receptor's extracellular domain binds apolipoprotein B-100 on LDL particles (~22 nm diameter, carrying ~1,500 cholesterol esters in a hydrophobic core). Binding occurs at neutral pH (7.4) on the cell surface. LDL receptors cluster spontaneously in coated pits even without ligand — unlike many signaling receptors that require ligand for clustering.

Step 3: Internalization. Clathrin-coated pits invaginate; dynamin mediates scission. The internalized coated vesicle (~100 nm) sheds its clathrin coat within seconds.

Step 4: Endosome acidification and sorting. The uncoated vesicle fuses with the early endosome (pH ~6.5 → 6.0). Acidification is driven by the V-ATPase proton pump. At low pH (~5.5 in late endosomes), the LDL receptor undergoes a conformational change, releasing LDL.

Step 5: Receptor recycling. The empty LDL receptor is sorted into tubular extensions of the early/sorting endosome and recycled back to the plasma membrane via recycling endosomes. A single LDL receptor makes ~150 round trips over its ~20-hour lifespan.

Step 6: Lysosomal degradation of LDL. LDL particles are delivered to late endosomes and then lysosomes. Lysosomal acid lipase (LAL) hydrolyzes cholesterol esters → free cholesterol, which exits the lysosome via NPC1/NPC2 proteins. Free cholesterol:

• Incorporates into cellular membranes
• Inhibits HMG-CoA reductase (the rate-limiting enzyme of cholesterol biosynthesis) via the SREBP-SCAP pathway
• Downregulates LDL receptor transcription (feedback regulation)

Disease and Clinical Relevance

Familial Hypercholesterolemia (FH)

FH is caused by mutations in the LDL receptor gene (LDLR), with five functional classes:

Pathophysiology: Heterozygous FH (~1 in 250–500) → ~50% functional LDL receptors → 2× normal plasma LDL → accelerated atherosclerosis → MI by age 40–50. Homozygous FH (~1 in 300,000–1,000,000) → <2% functional LDL receptors → 6× normal plasma LDL → MI in childhood/adolescence.

Treatment reflects mechanism:

• Statins inhibit HMG-CoA reductase → reduce cholesterol synthesis → upregulate LDL receptor (via SREBP) → partially compensate
• PCSK9 inhibitors (alirocumab, evolocumab): PCSK9 binds LDL receptor and targets it for lysosomal degradation. Blocking PCSK9 increases LDL receptor half-life → enhanced LDL clearance.
• Ezetimibe blocks intestinal cholesterol absorption.

Other Clinical Connections

Energy and Directionality

• COPII budding: Sar1 GTP cycle (1 GTP)
• COPI retrograde transport: Arf1 GTP cycle (1 GTP)
• Intra-Golgi transport: COPI vesicle cycling + cisternal maturation driven by COPI retrograde flow
• Endosome acidification: V-ATPase hydrolyzes ATP to pump protons (2 H⁺ per ATP)
• Lysosomal degradation: ATP for V-ATPase (~pH 4.5–5.0 maintained)
• Receptor recycling: Sorting into recycling tubules is energy-dependent, driven by Rab11 and actin

Experimental Evidence

• Pulse-chase autoradiography (Palade, 1960s): Radiolabeled amino acids tracked through ER → Golgi → secretory granules → secretion in pancreatic acinar cells. Nobel Prize 1974. Established the secretory pathway.
• LDL receptor pathway (Goldstein & Brown, 1970s–80s): Fibroblasts from FH patients showed defective LDL binding/internalization/degradation; established receptor-mediated endocytosis paradigm. Nobel Prize 1985.
• Cisternal maturation (Losev et al., 2006; Matsuura-Tokita et al., 2006): Live-cell imaging of GFP-tagged Golgi residents in yeast showed individual cisternae change color (cis → trans markers) over time.
• Procollagen transport (Bonfanti et al., 1998): Procollagen aggregates (~300 nm) cannot fit into COPI vesicles yet traverse the Golgi, providing strong evidence for cisternal maturation.
• Synaptic vesicle cycle (Heuser & Reese, 1973; Ceccarelli et al., 1973): Electron microscopy of stimulated frog neuromuscular junctions showed depletion of synaptic vesicles and increased coated pits/vesicles, demonstrating clathrin-mediated recycling.

High-Yield Summary

1. The secretory pathway: ER → ERES (COPII) → ERGIC → cis/medial/trans-Golgi (COPI retrograde) → TGN (sorting).
2. Golgi transport blends cisternal maturation (procollagen) with COPI vesicular retrograde recycling of enzymes.
3. Constitutive secretion = continuous; regulated secretion = signal-triggered (Ca²⁺ for neurotransmitters).
4. Three endocytosis types: pinocytosis (non-specific), phagocytosis (large particles, actin-driven), receptor-mediated (clathrin, specific).
5. LDL receptor pathway: surface binding → clathrin-coated pit → endosome acidification → LDL release → receptor recycles → lysosomal cholesterol release → feedback on synthesis.
6. Familial hypercholesterolemia: LDLR mutations in any of 5 functional classes → elevated plasma LDL → accelerated atherosclerosis.

Questions

Q1: A mutation in the KDEL receptor prevents it from binding KDEL-bearing proteins. Trace the consequences from the Golgi back to the ER, and explain why the cell eventually dies.

Q2: Contrast the mechanism of Ca²⁺-triggered neurotransmitter release with constitutive secretion. Why does the synapse need regulated rather than constitutive release?

Q3: A patient with homozygous familial hypercholesterolemia has LDL receptor mutations that permit LDL binding and internalization but prevent LDL release in endosomes (Class V). Explain why their plasma LDL is still elevated even though LDL enters cells.

Common Misconceptions

1. "All secretion goes through clathrin-coated vesicles." — FALSE. Constitutive secretion from the TGN to the plasma membrane does NOT involve clathrin. Clathrin at the TGN directs vesicles to endosomes.
2. "The Golgi is a static structure with vesicles shuttling between fixed cisternae." — Partially false. Cisternal maturation means individual cisternae are dynamic, not permanent, structures.
3. "Phagocytosis and pinocytosis are just variations of receptor-mediated endocytosis." — FALSE. Phagocytosis is actin-driven and particle-triggered. Pinocytosis can be clathrin-independent. They are mechanistically distinct.
4. "Endosome acidification is for lysosomal enzyme activity." — Partially true, but acidification of early endosomes (pH ~6.0–6.5, not the ~4.5–5.0 of lysosomes) primarily drives ligand-receptor dissociation (LDL, transferrin), not degradation.